PSC
CRSP icon

Prentiss Smith & Co’s CRISPR Therapeutics CRSP Stock Holding History

Prentiss Smith & Co’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-1,464
Closed -$237K – 76
2021
Q2 		$237K Buy
+1,464
New +$178K 0.11% 72

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $23.2B AUM 40.19% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Prentiss Smith & Co's CRSP Position: Q3 2021 in Review

Prentiss Smith & Co sold out of CRISPR Therapeutics (CRSP) in Q3 2021, closing a stake of 1,464 shares — an estimated $237K sold.

Prentiss Smith & Co first reported a position in CRSP in Q2 2021 and held it in 1 quarter. The position peaked at $237K in Q2 2021. 474 funds tracked by Wall St. Rank hold CRSP as of Q3 2021.

  • Prentiss Smith & Co reported no remaining CRISPR Therapeutics position as of Q3 2021 after selling out during the quarter.
  • Prentiss Smith & Co sold 1,464 CRISPR Therapeutics shares in Q3 2021, an estimated $237K.
  • Prentiss Smith & Co first reported a position in CRISPR Therapeutics in Q2 2021 and held it in 1 quarter.
  • Prentiss Smith & Co's CRISPR Therapeutics position peaked at $237K in Q2 2021.
  • 474 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q3 2021.

Based on Prentiss Smith & Co's 13F filing for Q3 2021, filed 19 Oct 2021.